New technology enables the insertion of a large segment of DNA into a genome, potentially expanding gene therapy treatment ...

That is because scientists keen to achieve more precise control over an organism’s genetics are experimenting with a ...

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

Profluent and Lilly teamed up on AI‑designed enzymes in a deal worth up to $2.25B. Big tech, bigger gene edits.

Frontier AI firm Profluent has entered a multi-program strategic research collaboration with Eli Lilly and Co. LLY to develop and commercialize custom site-specific recombinases to treat genetic ...

Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the Big Pharma team up with Profluent to ...

Eli Lilly and Co. is taking another step to bolster its genetic medicine portfolio, this time through a $2.25 billion deal ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...

Retrons adapted from E. coli enable genome editing in 15 diverse bacterial species, expanding recombineering tools across major microbial phyla.

Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...

Researchers from Wageningen University & Research and Van Andel Institute used a variant of CRISPR, a gene-editing tool, to ...

The CRISPR gene editing technique has had a dramatic influence on biomedical research, and has even been applied to a few humans to treat disease. Since its invention, scientists have improved, ...